Biomolecules & Therapeutics

  • 제18권1호
  • /
  • Pages.65-70
  • /
  • 2010
  • /
  • 1976-9148(pISSN)
  • /
  • 2005-4483(eISSN)
한국응용약물학회 (The Korean Society of Applied Pharmacology)
권호 표지
DOI QR코드

DOI QR Code

The Inhibitory Effect of Rivastigmine and Galantamine on Choline Transport in Brain Capillary Endothelial Cells

  • Lee, Na-Young (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Sookmyung Women's University) ;
  • Kang, Young-Sook (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Sookmyung Women's University)
  • 발행 : 2010.01.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The blood-brain barrier (BBB) transport of acetylcholinesterase (AChE) inhibitors, donepezil and tacrine suggested to be mediated by choline transport system in our previous study. Therefore, in the present study, we investigated the interaction of other AChE inhibitors, rivastigmine and galantamine with choline transporter at the BBB. The effects of rivastigmine and galantamine on the transport of choline by conditionally immortalized rat brain capillary endothelial cell lines (TR-BBB cells) were characterized by cellular uptake study using radiolabeled choline. The uptake of [$^3H$]choline was inhibited by rivastigmine and galantamine, with $IC_{50}$ values (i.e. concentration necessary for 50% inhibition) for 1.13 and 1.15 mM, respectively. Rivastigmine inhibited the uptake of [$^3H$]choline competitively with $K_i$ of 1.01 mM, but galantamine inhibited noncompetitively. In addition, the efflux of [$^3H$]choline was significantly inhibited by rivastigmine and galantamine. Our results indicated that the BBB choline transporter may be involved in a part of the influx and efflux transport of rivastigmine across the BBB. These findings should be therapeutically relevant to the treatment of Alzheimer's disease (AD) with AChE inhibitors, and, more generally, to the BBB transport of CNS-acting cationic drugs via choline transporter.

키워드

참고문헌

  1. Allen, D. D., Lockman, P. R., Roder, K. E., Dwoskin, L. P. and Crooks, P. A. (2003). Active transport of high-affinity choline and nicotine analogs into the central nervous system by the blood-brain barrier choline transporter. J. Pharmacol. Exp. Ther. 304, 1268-1274. https://doi.org/10.1124/jpet.102.045856
  2. Allen, D. D. and Smith, Q. R. (2001). Characterization of the blood-brain barrier choline transporter using the in situ rat brain perfusion technique. J. Neurochem. 76, 1032-1041. https://doi.org/10.1046/j.1471-4159.2001.00093.x
  3. Cohen, B. M., Renshaw, P. F., Stoll, A. L., Wurtman, R. J., Yurgelun-Todd, D. and Babb, S. M. (1995). Decreased brain choline uptake in older adults: an in vivo proton magnetic resonance spectroscopy study. J. Am. Med. Assoc. 274, 902-907. https://doi.org/10.1001/jama.274.11.902
  4. Cornford, E. M., Braun, L. D. and Oldendorf, W. H. (1978). Carrier mediated blood-brain barrier transport of choline and certain analogs. J. Neurochem. 30, 299-308. https://doi.org/10.1111/j.1471-4159.1978.tb06530.x
  5. Hosoya, K. I., Ohtsuki, S. and Terasaki, T. (2002). Recent advances in the brain-to-blood efflux transport across the blood-brain barrier. Int. J. Pharm. 248, 15-29. https://doi.org/10.1016/S0378-5173(02)00457-X
  6. Hosoya, K. I., Takashima, T., Tetsuka, K., Nagura, T., Ohtsuki, S., Takanaga, H., Ueda, M., Yanai, N., Obinata, M. and Terasaki, T. (2000). mRNA expression and transport characterization of conditionally immortalized rat brain capillary endothelial cell lines, a new in vitro BBB model for drug targeting. J. Drug Target. 8, 357-370. https://doi.org/10.3109/10611860008997912
  7. Jann, M. W., Shirley, K. L. and Small, G. W. (2002). Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin. Pharmacokinet. 41, 719-739. https://doi.org/10.2165/00003088-200241100-00003
  8. Kang, Y. S., Terasaki, T., Ohnishi, T. and Tsuji, A. (1990). In vivo and in vitro evidence for a common carrier mediated transport of choline and basic drugs through the blood-brain barrier. J. Pharmacobiodyn. 13, 353-360. https://doi.org/10.1248/bpb1978.13.353
  9. Kang, Y. S., Lee, K. E., Lee, N. Y. and Terasaki, T. (2005). Donepezil, tacrine and alpha-phenyl-n-tert-butyl nitrone (PBN) inhibit choline transport by conditionally immortalized rat brain capillary endothelial cell lines (TR-BBB). Arch. Pharm. Res. 28, 443-450. https://doi.org/10.1007/BF02977674
  10. Kang, Y. S., Ohtsuki, S., Takanaga, H., Tomi, M., Hosoya, K. and Terasaki, T. (2002). Regulation of taurine transport at the blood-brain barrier by tumor necrosis factor-alpha, taurine and hypertonicity. J. Neurochem. 83, 1188-1195. https://doi.org/10.1046/j.1471-4159.2002.01223.x
  11. Kim, M. H., Maeng, H. J., Yu, K. H., Lee, K. R., Tsuruo, T., Kim, D. D., Shim, C. K. and Chung, S. J. (2009). Evidence of carrier-mediated transport in the penetration of donepezil into the rat brain. J. Pharm. Sci. 99, 1548-1566.
  12. Lee, N. Y. and Kang, Y. S. (2006). In vivo brain-to-blood efflux transport of choline at the blood-brain barrier. J. Appl. Pharmacol. 14, 45-49.
  13. Lee, N. Y. and Kang, Y. S. (2008). The efflux transport of choline through blood-brain barrier is inhibited by Alzheimer's disease therapeutics. Biomol. & Ther. 16, 179-183. https://doi.org/10.4062/biomolther.2008.16.3.179
  14. Matsui, K., Mishima, M., Nagai, Y., Yuzuriha, T. and Yoshimura, T. (1999). Absorption, Distribution, Metabolism, and Excretion of Donepezil (Aricept) after a Single Oral Administration to Rat. Drug Metab. Dispos. 27, 1406-1414.
  15. McNally, W. P., Pool, W. F., Sinz, M. W., Dehart, P., Ortwine, D. F., Huang, C. C., Chang, T. and Woolf, T. F. (1996). Distribution of tacrine and metabolites in rat brain and plasma after single- and multiple-dose regimens; Evidence for accumulation of tacrine in brain tissue. Drug Metab. Dispos. 24, 628-633.
  16. Metting, T. L., Burgio, D. E., Terry, A. V., Beach, J. W., Mccurdy, C. R. and Allen, D. D. (1998). Inhibition of brain choline uptake by isoarecolone and lobeline derivatives: implications for potential vector-mediated brain drug delivery. Neurosci. Let. 258, 25-28. https://doi.org/10.1016/S0304-3940(98)00871-4
  17. Murakami, H., Takanaga, H., Matsuo, H., Ohtani, H. and Sawada, Y. (2000). Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique. Am. J. Physiol. Heart Circ. Physiol. 279, H1022-1028. https://doi.org/10.1152/ajpheart.2000.279.3.H1022
  18. Ohtsuki, S. and Terasaki T. (2007). Contribution of carriermediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm. Res. 24, 1745-1758. https://doi.org/10.1007/s11095-007-9374-5
  19. Pardridge, W. M. (1988). Recent advances in blood-brain barrier transport. Annu. Rev. Pharmacol. Toxicol. 28, 25-39. https://doi.org/10.1146/annurev.pa.28.040188.000325
  20. Polinsky, R. J. (1998). Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin. Ther. 20, 634-647. https://doi.org/10.1016/S0149-2918(98)80127-6
  21. Sawada, N., Takanaga, H., Matsuo, H., Naito, M., Tsuruo, T. and Sawada, Y. (1999). Choline uptake by mouse brain capillary endothelial cells in culture. J. Pharm. Pharmacol. 51, 847-852. https://doi.org/10.1211/0022357991773050
  22. Sung, J. H., Yu, K. H., Park, J. S., Tsuruo, T., Kim, D. D., Shim, C. K., Chung, S. J. (2005). Saturable distribution of tacrine into the striatal extracellular fluid of the rat: evidence of involvement of multiple organic cation transporters in the transport. Drug. Metab. Dispos. 33, 440-448. https://doi.org/10.1124/dmd.104.002220
  23. Takanaga, H., Tokuda, N., Ohtsuki, S., Hosoya, K. and Terasaki, T. (2002). ATA2 is predominantly expressed as system A at the blood-brain barrier and acts as brain-toblood efflux transport for L-proline. Mol. Pharmacol. 61, 1289-1296. https://doi.org/10.1124/mol.61.6.1289
  24. Terasaki, T., Ohtsuki, S., Hori, S., Takanaga, H., Nakashima, E. and Hosoya, K. (2003). New approaches to in vitro models of blood-brain barrier drug transport. Drug Discov. Today. 8, 944-954. https://doi.org/10.1016/S1359-6446(03)02858-7
  25. Tiseo, P. J., Rogers, S. L. and Friedhoff, L. T. (1998). Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br. J. Clin. Pharmacol. 46, 13-18. https://doi.org/10.1046/j.1365-2125.1998.0460s1013.x

피인용 문헌

  1. The Acetylcholinesterase Inhibitors Competitively Inhibited an Acetyl l-Carnitine Transport Through the Blood–Brain Barrier vol.37, pp.7, 2012, https://doi.org/10.1007/s11064-012-0723-3
  2. Rivastigmine Transdermal Patch 13.3 mg/24 h: A Review of Its Use in the Management of Mild to Moderate Alzheimer’s Dementia vol.31, pp.8, 2014, https://doi.org/10.1007/s40266-014-0197-x
  3. 6-Mercaptopurine Transport by Equilibrative Nucleoside Transporters in Conditionally Immortalized Rat Syncytiotrophoblast Cell Lines TR-TBTs vol.100, pp.9, 2011, https://doi.org/10.1002/jps.22631
  4. Inhibitors of Acetylcholinesterase and Butyrylcholinesterase Meet Immunity vol.15, pp.6, 2014, https://doi.org/10.3390/ijms15069809
  5. Docking-based design and synthesis of galantamine-camphane hybrids as inhibitors of acetylcholinesterase 2017, https://doi.org/10.1111/cbdd.12991
  6. Rivastigmine Transdermal Patch vol.71, pp.9, 2011, https://doi.org/10.2165/11206380-000000000-00000
  7. Novel hits for acetylcholinesterase inhibition derived by docking-based screening on ZINC database vol.33, pp.1, 2018, https://doi.org/10.1080/14756366.2018.1458031
  8. Involvement of a Novel Organic Cation Transporter in Paeonol Transport Across the Blood-Brain Barrier vol.27, pp.3, 2010, https://doi.org/10.4062/biomolther.2019.007
  9. Inhibiting Acetylcholinesterase to Activate Pleiotropic Prodrugs with Therapeutic Interest in Alzheimer’s Disease vol.24, pp.15, 2010, https://doi.org/10.3390/molecules24152786
  10. Models for skin and brain penetration of major components from essential oils used in aromatherapy for dementia patients vol.38, pp.8, 2010, https://doi.org/10.1080/07391102.2019.1633408
  11. A Novel Galantamine-Curcumin Hybrid as a Potential Multi-Target Agent against Neurodegenerative Disorders vol.26, pp.7, 2010, https://doi.org/10.3390/molecules26071865